Last updated on June 2016

A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Crenezumab in patients with prodromal to mild Alzheimer's Disease.


Brief description of study

A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Crenezumab in patients with prodromal to mild Alzheimer's Disease.

Detailed Study Description

Alzheimer’s disease (AD) is the most common cause of dementia. The deposition of extracellular amyloid plaques in the brain is a hallmark pathological finding in AD. These amyloid plaques are primarily composed of Aβ peptides. This study is to evaluate crenezumab, a monoclonal antibody, that has been shown to inhibit self-association and aggregation of Aβ peptides.

Clinical Study Identifier: TX144040

Contact Investigators or Research Sites near you

Start Over

Jill Smith

University of South Florida-Morsani College of Medicine
Tampa, FL USA
  Connect »